A new Tel Aviv University study identifies a previously unknown mechanism involved in the development of Lou Gehrig’s disease, or amyotrophic lateral sclerosis (ALS)....

Israeli biotechnology company Kadimastem has received approval from the IRB (Helsinki Committee) of the Hadassah Ein Kerem Hospital for the phase I/IIa clinical trial...

A new ALS treatment utilizing a stem cell infusion protocol performed at Hadassah Medical Organization (HMO) and developed by the US/Israeli biotech company BrainStorm...